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Letters to the Editor
Cost-Effectiveness of Upstream
Versus Selective Glycoprotein
IIb/IIIa Inhibitors for Acute
Coronary Syndromes
As a result of extensive clinical research during the past decades,
various treatment options are available today that might improve
the prognosis of patients with coronary disease. One of the
challenges for contemporary medicine is to implement these
therapies rationally in clinical practice, in the appropriate patients
at the appropriate time. In cost-conscious environments, treatment
decisions should not only be based on the suspected benefit/harm
ratio, but also on insights into therapy-related costs. Hence,
pharmaco-economical analyses are becoming increasingly impor-
tant in clinical cardiology.
In a recent issue of JACC, Glaser et al. (1) presented the results
of a pharmaco-economical analysis in patients presenting with
acute coronary syndromes (ACS) with moderate or high risk for
cardiovascular events. They concluded that the strategy of routine
upstream use of small-molecule (upstream-SM) glycoprotein (GP)
IIb/IIIa inhibitors is a more cost-effective approach than the
strategy of selective use of abciximab in patients who ultimately
undergo percutaneous coronary intervention (PCI).
Glaser et al. (1) performed a decision-tree analysis and used data
from clinical trials and a meta-analysis to define the probabilities on
the decision nodes. However, several discrepancies exist between the
applied probabilities and the data presented in the studies cited, most
of which favor the upstream-SM strategy. As an example, Glaser
assumes a relative risk (RR) in the range 0 (favoring upstream-SM) to
2.5 (favoring abciximab) for the incidence of death and myocardial
infarction (MI) in the PCI setting; yet according to the TARGET
(Do Tirofiban and ReoPro Give Similar Efficacy Outcomes?) trial, in
ACS patients the 95% confidence intervals (CIs) are 0.4 to 2.5 for
death and 1.1 to 2.0 forMI (2). Interestingly, the RR of 0 implies that
the upstream-SM strategy could produce survival for sure, which is
unrealistic. Glaser assumes a RR of 1.0 for major bleeding complica-
tions in patients undergoing PCI, whereas the TARGET trial reports
1.0% major bleeds after upstream-SM versus 0.7% after abciximab
(2). As a final example, Glaser et al. (1) assumes that the
upstream-SM strategy, as compared to control therapy, is associated
with a RR of 0.88 for death as well as for MI, with ranges varying
from 0.41 to 0.47 to 0.95. In fact, the meta-analysis of the corre-
sponding trials showed a 95% CI for the odds ratio of the composite
end point of 0.82 to 0.95 (3).
If all variations between the assumptions of Glaser et al. (1) and
the original studies are adjusted, results of the pharmaco-
economical analysis are reversed: the selective abciximab strategy is
then associated with a gain of 1,661 life-years per 100,000 patients,
and avoids 173 major bleeds, as compared to upstream-SM. Still,
this finding is unreliable. In fact, the presented decision-tree model
was insufficiently adjusted for uncertainty because the sensitivity
analysis that was applied did not alter all parameters at the same
time. Monte-Carlo simulation demonstrates a tremendous uncer-
tainty in any result of this study overall.
Decision-tree analyses might be useful to help clinicians make
rational, consistent, and cost-conscious decisions. However, given
the fact that average readers of clinical journals, including JACC,
are not specialists in medical decision making and pharmaco-
economics, authors of such analyses should be highly transparent
in their choices, and they should emphasize the uncertainties of
their conclusions. I am afraid that Glaser and colleagues missed
opportunities in this respect.
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